Goldman Sachs’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-41,700
| Closed | -$120K | – | 6574 |
|
|
2017
Q4 | $120K | Sell |
41,700
-23,100
| -36% | -$83.9K | ﹤0.01% | 5681 |
|
|
2017
Q3 | $291K | Buy |
64,800
+37,900
| +141% | +$168K | ﹤0.01% | 5494 |
|
|
2017
Q2 | $123K | Sell |
26,900
-14,600
| -35% | -$58.7K | ﹤0.01% | 6042 |
|
|
2017
Q1 | $175K | Sell |
41,500
-9,900
| -19% | -$41.1K | ﹤0.01% | 5803 |
|
|
2016
Q4 | $212K | Sell |
51,400
-14,000
| -21% | -$74.4K | ﹤0.01% | 5731 |
|
|
2016
Q3 | $530K | Buy |
65,400
+41,000
| +168% | +$349K | ﹤0.01% | 4985 |
|
|
2016
Q2 | $190K | Sell |
24,400
-141,000
| -85% | -$1.21M | ﹤0.01% | 5733 |
|
|
2016
Q1 | $1.28M | Sell |
165,400
-1,549,800
| -90% | -$11.4M | ﹤0.01% | 3874 |
|
|
2015
Q4 | $18.5M | Buy |
1,715,200
+131,200
| +8% | +$1.19M | 0.01% | 1809 |
|
|
2015
Q3 | $10.9M | Buy |
1,584,000
+18,300
| +1% | +$149K | ﹤0.01% | 2184 |
|
|
2015
Q2 | $13.9M | Buy |
1,565,700
+631,700
| +68% | +$5.98M | ﹤0.01% | 2083 |
|
|
2015
Q1 | $9.21M | Sell |
934,000
-1,174,400
| -56% | -$14.7M | ﹤0.01% | 2359 |
|
|
2014
Q4 | $25.8M | Sell |
2,108,400
-791,600
| -27% | -$9.67M | 0.01% | 1636 |
|
|
2014
Q3 | $28.9M | Buy |
2,900,000
+50,000
| +2% | +$464K | 0.01% | 1509 |
|
|
2014
Q2 | $21.6M | Hold |
2,850,000
| – | – | 0.01% | 1728 |
|
|
2014
Q1 | $9.38M | Sell |
2,850,000
-1,659,200
| -37% | -$5.81M | ﹤0.01% | 2426 |
|
|
2013
Q4 | $15M | Buy |
4,509,200
+1,436,300
| +47% | +$4.17M | ﹤0.01% | 1998 |
|
|
2013
Q3 | $9.28M | Buy |
3,072,900
+2,072,400
| +207% | +$14.2M | ﹤0.01% | 2331 |
|
|
2013
Q2 | $8.18M | Buy |
+1,000,500
| New | +$7.64M | ﹤0.01% | 2268 |
|
Goldman Sachs's ACHN Position: Q1 2020 in Review
Goldman Sachs sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 3,048,297 shares — an estimated $18.4M sold.
Goldman Sachs first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $64.5M in Q4 2014. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Goldman Sachs reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Goldman Sachs sold 3,048,297 Achillion Pharmaceuticals shares in Q1 2020, an estimated $18.4M.
- Goldman Sachs first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Goldman Sachs's Achillion Pharmaceuticals position peaked at $64.5M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Goldman Sachs's 13F filing for Q1 2020, filed 15 May 2020.